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HIV treatment has been greatly impacted by transmitted resistance to antiretrovirals (ARV). Several 
studies have documented resistance in naïve individuals and estimates of transmitted drug resistance 
mutations range from <5% to as high as 25%.  Washington, D.C. has one of the highest human 
immunodeficiency virus (HIV) prevalence rates in the United States (3.2% in 2009), but local data 
regarding the frequency of major mutations and antiretroviral (ARV) resistance has been 
limited. Medical records of HIV positive, ARV-naïve adults at two facilities in Washington, D.C., The 
George Washington University Medical Center and the Veterans Affairs Medical Center, were 
retrospectively analyzed in subjects who had genotypic resistance testing from 2007 to 2010. Of 407 
ARV-naïve patients, at least one transmitted drug resistance mutation was detected in 17% of our 
patients, with non-nucleoside reverse transcriptase (NNRTI) mutations observed in 15%. Among 
patients with at least one reverse transcriptase (RT) or major protease region (Pr) resistance mutation, 
85% had resistance against a single ARV class. Dual and triple class resistance mutations were seen in 
8 patients (2%) and 3 patients (0.7%), respectively.  Most of the multiple class resistance was seen in 
2010.  A gradual increase in NNRTI resistance was noted during 2008 to 2010. Our prevalence of 
transmitted RT, major Pr mutations (17.4%) and ARV resistance (8.6%) were high but similar to rates 
reported by others within the United States.  Given the high HIV prevalence in the District of Columbia, 
this has important implications for treatment of these ARV-naïve patients.  
 
Key words:  HIV, Washington D.C., naïve to antiretrovirals, transmitted drug resistance, transmitted drug 
resistance mutations, antiretroviral mutations. 
 
 
INTRODUCTION 
 
Human immunodeficiency virus (HIV) treatment has been 
greatly impacted by transmitted drug resistance (TDR) 
mutations to antiretroviral (ARV) agents. Based on United 
States Department of Health and Human Services 
(DHHS) guidelines, genotypic antiretroviral resistance 
testing (GART) was initially given CIII and DIII 
recommendations in 2000 for acutely-infected and 
chronically-infected treatment-naïve patients, 
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respectively, and then an AIII recommendation for all 
treatment-naïve patients entering care in 2007 (DHHS, 
2007). For ARV treatment naïve individuals in the U.S., 
TDR mutation rates have ranged from about 5% to as 
high as 25% (Castor et al., 2012; Huaman et al., 2011; 
Hurt et al., 2009; Little et al., 1999; Little et al., 2002; 
MacVeigh et al., 2013; Readhead et al., 2012; Ross et 
al., 2007; Taniguchi et al., 2012; Truong et al., 2011; 
Weinstock et al., 2000; Weinstock et al., 2004; Wheeler 
et al., 2010; Yanik et al., 2012; Youmans et al., 2011).  
TDR has several important implications. TDR has been 
demonstrated to increase the risk of poor outcomes, 
including an increase in time to achieve virologic 
suppression, risk of virologic failure, and a more rapid 
decline in CD4 counts in the first year after diagnosis. 
(Grant et al., 2002; Little et al., 2002; Pillay et al., 2006; 
Taniguchi et al., 2012; Wittkop et al., 2011). 
Knowledge about TDR is particularly important in 
Washington, D.C., which has one of the highest HIV 
prevalence rates in the United States (DC HAHSTA, 
2010; CDC Surveillance, 2011). In 2009, the HIV 
seropositivity rate in residents of Washington, D.C. aged 
13 or older was 3.2% (DC HAHSTA, 2010). The rate of 
HIV infection in African Americans was 4.7%, including 
7.1% in African American males (DC HAHSTA, 2010).   
Among all individuals from Washington, D.C. aged 40 to 
49 and 50 to 59 in 2009, 7.4 and 6.1% were infected with 
HIV, respectively (DC HAHSTA, 2010). The rate in 
Washington, D.C. exceeds the rate of a general epidemic 
as defined by World Health Organization and the rate of 
HIV in some countries who received the United States 
President’s Emergency Plan for AIDS Relief (Nybo and 
Barrere, 2012).  TDR in several communities has been 
studied but data regarding the frequency of major 
mutations and ARV resistance in Washington, D.C. is 
limited.  In the retrospective review by (Boyd et al., 2008) 
of 42 treatment-naïve patients in Washington, D.C. who 
entered medical care in 2005, 7% of patients were 
classified as having International AIDS Society (IAS) 
recognized mutations detected in the reverse 
transcriptase (RT) region; no major mutations were 
detected in the protease (Pr) region. Major nucleoside 
reverse transcriptase inhibitor (NRTI) and non-nucleoside 
reverse transcriptase inhibitor (NNRTI) resistance 
mutations were detected in 2.4% and 4.8% of patients, 
respectively (Boyd et al. 2008). Gajjala et al. (2008) 
identified 41 patients newly diagnosed with HIV in 
Washington, D.C. from 2005 to 2007; no major NRTI or 
Pr mutations were detected; 3 patients had major NNRTI 
mutations (2.4%) (Gajjala et al. 2008). In this study, the 
authors sought to further assess the frequency of TDR 
mutations and ARV resistance among treatment-naïve 
patients in Washington, D.C.       
 
 
METHODOLOGY 
 
After approval by the Institutional Review Boards of two  facilities  in 
 
 
 
 
Washington, D.C., The George Washington University Medical 
Center (GWUMC) and the Veterans Affairs Medical Center (VAMC), 
as well as the Research & Development Committee at the VAMC, a 
retrospective review at GWUMC and the VAMC was performed for 
all patients age 18 or older, who had a GART from 1 January, 2007 
to 31 December, 2010.  Medical record review was completed to 
verify that the GART was performed when the patient was ARV-
naïve. Data for age, gender, race/ethnicity, CD4 count and 
percentage, and HIV RNA copies were collected. GART results for 
patients at the VAMC used the TRUGENE® HIV-1 Genotyping 
Assay, versions 11-15 (Siemens HealthCare Diagnostics, Inc., 
Tarrytown, NY).  Genotypes for patients at GWUMC were done 
either by GenoSURE® (LabCorp, Burlington, NC), Quest HIV-1 
Genotype (Quest Diagnosics, Madison, NY),  ViroSeq™ v. 2.6, 2.8 
(Celera, Alameda, CA), or vircoTYPE™ HIV-1 VPT 4.1.01, 4.2.01, 
and 4.3.01 (Janssen Diagnostics, Mechelen, Belgium).  RT and Pr 
mutations, as identified in the 2010 IAS-USA mutation list, and 
interpreted ARV resistance were recorded for each patient based 
on the genotype results provided by the test report.  Genotypic 
resistance to integrase inhibitors was not determined. 
 
 
RESULTS 
 
A total of 1944 genotypes were ordered from 2007 to 
2010 at the two institutions in this study. A total of 407 
individuals naïve to ARVs based on chart review were 
identified.  Of 407 ARV-naïve patients who had GART 
during 2007 to 2010, 277 were in care at GWUMC and 
130 at the VAMC.  The median age was 43.  Men 
comprised the majority (81%) of the patients; no women 
from the VAMC cohort met our inclusion criteria.  The 
majority (79%) of our patients were African American.  
The median CD4 count was 287 (interquartile range 107 
to 439) cells/mm
3
; 144 patients (36%) had a CD4 count 
<200 cells/mm
3
.  HIV RNA in copies/mL was distributed 
as follows:  >100,000: 129 patients (32%); 10,000-
100,000: 173 patients (43%); and <10,000: 96 patients 
(25%).  
For our cohort during 2007 to 2010, 72 patients (17%) 
demonstrated at least one mutation for any RT or major 
Pr mutation.  Among all study patients, 70 (17%) had at 
least one RT mutation, where 16 patients (3.9%) had at 
least one NRTI mutation, and 62 (15%) had at least one 
NNRTI mutation.  Eight patients (2.0%) had a major Pr 
mutation. The majority of patients (85%) with at least one 
RT or major Pr mutation had resistance to a single ARV 
class.  Eight patients had dual class resistance 
mutations, 5 with NRTI and NNRTI mutations and 3 with 
NNRTI and Pr mutations. Three patients had triple class 
resistance mutations.  Of the 11 patients with resistance 
mutations to more than one class of ARVs, 8 had a 
GART performed in 2010.  In 2010, 6.6% of patients who 
had a GART had multiple class resistance mutations, as 
summarized in Table 1.   
Table 2 summarizes the frequency of RT and major Pr 
mutations seen in our cohort.  The most common RT 
mutations were K103N (5.2%), V90I and V179D (both 
2.5%), and M41L (1.7%).  Eight patients (1.96%) had 
E138A/G/K.  Major Pr mutations were rare and 
accounted for rates of <1%.  However, there was
Swierzbinski  et  al.         51 
 
 
 
Table 1. Summary of mutations and mutations by drug class, where the percent of nucleoside/nucleotide reverse transcriptase 
inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), protease gene (Pr) mutations and multiclass resistance 
mutations were given by year. 
 
Year N 
Any RT or major Pr 
mutation (%) 
NRTI  class 
mutation (%) 
NNRTI class 
Mutation (%) 
Major 
Pr mutation 
(%) 
2 or more ARV class 
mutations (%) 
2007 74 9.5 4.1 6.8 0 1.4 
2008 99 16 1 15 0 0 
2009 113 15 2.7 12.4 2 1.8 
2010 121 26 7.4 23 4 6.6 
 
 
 
Table 2.  Summary of reverse transcriptase (RT) and major protease 
(Pr) gene mutations, where numbers and percent of total of treatment-
naïve patients are given. 
 
RT mutation Frequency (%)  Pr mutation Frequency (%) 
K103N 22 (5.2)  V82A 3 (<1) 
V90I 10 (2.5)  L90M 3 (<1) 
V179D 10 (2.5)  M46L 2 (<1) 
M41L 7 (1.7)  I47V 2 (<1) 
E138A/G/K 8 (1.7)  I54M 2 (<1) 
G190A 5 (1.2)  M46I 1 (<1) 
V108I 5 (1.2)  D30N 1 (<1) 
 
 
 
an increasing trend from 2007 to 2010 for any detected 
RT or major Pr mutation.  This increase was primarily due 
to NNRTI mutations, as summarized in Table 1. 
Among those with any interpreted ARV resistance, 35 
(8.6%) patients demonstrated resistance to at least 1 
ARV drug, such that 3 (0.7%) patients had resistance to 
>1 NRTI, 28 (6.9%) had resistance to >1 NNRTI, and 10 
(2.5%) had resistance to >1 protease inhibitor (PI). While 
the majority of patients with any interpreted ARV 
resistance had resistance to a single class of ARVs 
(86%), 4 patients (0.98%) had dual class resistance (one  
with NRTI and NNRTI and three with NNRTI and PI), and 
a single patient had triple class resistance.  There was a 
gradual increase in resistance to NNRTIs during 2007 to 
2010. 
 
 
DISCUSSION 
 
We detected at least one TDR mutation in 17% of our 
patients during 2007 to 2010, with mutations of 15% for 
NNRTI, 3.9% for NRTI, and 2.0% for PI classes. Our 
overall TDR and resistance for specific ARV classes were 
higher than what was previously reported for Washington, 
D.C. by Boyd et al. (2005) and Gajjala et al. (2005-2007).
  
(Boyd et al., 2008; Gajjala et al., 2008).  Our patient 
population is similar to the HIV population in Washington, 
D.C.  Data in 2009 from the Washington, D.C. 
Department of Health revealed of individuals infected with 
HIV in our city, 72% were men and 75% African 
American, which are similar to the demographics of the 
population in our study (DC HAHSTA, 2010). There are 
other similarities in demographic and clinical data from 
the Department of Health and our population, including 
sex, ethnicity, age, and CD4 count at the time of 
diagnosis (DC HAHSTA, 2010).  
The differences in TDR within our region with similar 
patient demographics may be related to many 
complicated factors such as provider preferences for 
ARVs during the study periods, adherence patterns, 
engagement in care, patient comorbidities and non-
medical issues.  We did not gather additional demo-
graphic information about our subjects or look into the 
effect of transmission clusters, which could also lead to 
different results from Boyd et al. (2008). 
We also did not assess acute versus chronic infection 
among our treatment-naïve cohort.  However, our overall 
TDR data mirror the mutation rates reported in other 
studies within the United States (Castor et al., 2012; 
Huaman et al., 2011; Hurt et al., 2009; Little et al., 1999; 
Little et al., 2002; MacVeigh et al., 2013; Readhead et al., 
2012; Ross et al., 2007; Truong et al., 2011; Weinstock et 
al., 2000; Weinstock et al., 2004; Wheeler et al., 2010; 
Yanik et al., 2012; Youmans et al., 2011).    
In addition, our rate of 15% NNRTI mutations 
contributing to NNRTI resistance  was  higher  than  what  
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was typically reported for this drug class  (Castor et al., 
2012;  Huaman et al., 2011;  Hurt et al., 2009; Little et al., 
2002; MacVeigh et al., 2013; Readhead et al., 2012; 
Ross et al., 2007; Taniguchi et al., 2012; Truong et al., 
2011; Weinstock et al., 2000; Weinstock et al., 2004; 
Wheeler et al., 2010; Yanik et al., 2012; Youmans et al., 
2011). The increase in TDR was primarily due to NNRTI 
mutations and occurred during the 4-year study period in 
a trend similar to other studies in the United States (Grant 
et al., 2002; Ross et al., 2008; Shet et al., 2006; Simon et 
al., 2002). This is most likely due to provider preference 
for single daily pill regimens and the low barrier to 
resistance for the NNRTI class.  
The most commonly detected RT mutations in our 
study were M41L for NRTIs and K103N for NNRTIs, 
which are among the most frequently reported in many 
studies (Castor et al., 2012; Huaman et al., 2011; Hurt et 
al., 2009; Little et al., 2002; MacVeigh et al., 2013; 
Readhead et al., 2012; Ross et al., 2007; Taniguchi et al., 
2012; Truong et al., 2011; Weinstock et al., 2004; 
Wheeler et al., 2010; Yanik et al., 2012; Youmans et al., 
2011).   We observed low rates of individual major Pr 
mutations, all below 1%; our overall rate of 2% major Pr 
mutations is slightly less than many other studies in the 
United States  (Castor et al., 2012; Huaman et al., 2011; 
Hurt et al., 2009; Little et al., 2002; MacVeigh et al., 2013; 
Readhead et al., 2012; Ross et al., 2007; Taniguchi et al., 
2012; Truong et al., 2011; Weinstock et al., 2000; 
Weinstock et al., 2004; Wheeler et al., 2010; Yanik et al., 
2012; Youmans et al., 2011). Although in the minority, 
persons with dual and triple class ARV resistance 
mutations were seen in 2% (8 patients) and 0.7% (3 
patients), respectively. 
Baseline GART results before initiating ARV therapy 
has been sensible for our patient care.   Approximately 
7% of our study population had interpreted baseline 
resistance to NNRTIs, an ARV class included as 
components of preferred and alternative regimens for 
patients naïve to ARVs by the DHHS guidelines (DHHS, 
2913). Resistance testing has been shown to be cost-
effective in the United States unless the local resistance 
is ≤1% (Sax et al., 2005). Due to the relatively low levels 
of Pr mutations, our findings also support the use of a 
boosted PI regimen when empiric ARV therapy must be 
initiated before GART results are available.  Knowledge 
of local resistance data will likely prove to be important 
for post-exposure prophylaxis regimens, as well as pre-
exposure prophylaxis for which the Centers for Disease 
Control has issued interim guidelines for men who have 
sex with men (MSM), heterosexual couples at high risk 
for HIV acquisition, and injection drug users (CDC PrEP 
MSM 2011; CDC PrEP Hetero 2012; CDC PrEP IV 
2013).  
This study has several limitations.  We believe the 
majority of our patients were chronically infected based 
on medical record review with only a few with 
acute/recent HIV infection.  In some studies, patients with 
 
 
 
 
acute/recent infections had a higher rate of detected TDR 
compared to patients  who  were  chronically  infected 
(Weinstock et al., 2004; Yanik et al., 2012). TDR 
mutations may have been underestimated as low 
prevalence mutations are not detected by most standard 
sequencing techniques unless the mutation is present in 
>10-30% of the population (Bellecave et al., 2013; 
Johnson et al., 2008).  In some cases, the wild-type virus 
may become the dominant virus and certain TDR 
mutations may not be detected in the absence of 
selective drug pressure, though this may occur only after 
several years (Gandhi et al., 2003; Little et al., 2008; 
Yerly et al., 2008). It is possible the TDR rate in 
Washington, D.C. may be higher than the observed rate 
of 17%. 
We observed an increasing trend of TDR mutations, 
especially for NNRTI mutations since 2007, which was 
the first year that GART received an AIII recommendation 
for all treatment-naïve patients by DHHS. The NNRTI 
mutation increase contributed to the overall TDR trend 
over the 4-year period. It is noteworthy that approximately 
2% of our patients had E138A/G/K mutations during 2007 
to 2010, as these mutations are associated with 
rilprivirine resistance.  Rilprivirine, a NNRTI approved in 
2011, has been included as a component of alternative 
regimens recommended by DHHS (DHHS, 2013). The 
rates of E138A/G/K mutations within our community may 
have an impact on successful virologic suppression of 
patients initiating therapy.  
The most common mode of HIV transmission in 
Washington, D.C. is MSM (38.8%), followed by 
heterosexual contact (27.2%), and intravenous drug use 
(16.2%) (DC HAHSTA, 2010). MSM has been associated 
with higher rates of TDR (Banez et al., 2014; Little et al., 
2002; Shet et al., 2006; Weinstock et al., 2004)  although 
this has not been observed in all studies (Readhead et al. 
2012). We did not collect data regarding risk factor(s) for 
HIV acquisition, but this warrants further investigation to 
determine the rate of TDR for this population compared 
to other risk groups in our city.  Our data spanned the 
period from 2007 to 2010.  Continued surveillance is 
important to follow the rising trend of TDR in Washington, 
D.C. and to compare this trend with other high HIV 
prevalence areas.  This will be addressed in an ongoing 
registry called “The DC Cohort,” a city-wide database of 
HIV infected patients at the major academic and 
community clinics in Washington, D.C. (DC Cohort, 
2013).  
 
 
CONCLUSION 
 
In summary, 17% of ARV-naïve HIV-infected patients had 
>1 genotypic mutation, and 8.6% had resistance to >1 
ARV drug from 2007 to 2010.  NNRTI mutations were 
seen in 15% patients, followed by 3.9% for NRTI and 2% 
for major Pr mutations.  We  had  an  increasing  trend  of  
 
 
 
 
NNRTI mutations during the study period.  Our study 
found higher local rates of overall TDR and NNRTI-
associated mutations than what was previously reported 
in Washington, D.C. Our mutation and resistance findings 
have important implications in treatment initiation and pre 
and post-exposure prophylaxis in an urban area with one 
of the highest prevalence rate of HIV within the United 
States.   
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